Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06685068 · ClinicalTrials.gov registry record · Phase 1

A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by Genmab.

Active
Registry status
Phase 1
Development phase
23
Enrollment target
4
Study locations

NCT06685068: Active Phase 1 study of Advanced Solid Tumor, sponsored by Genmab.

NCT06685068 is a Phase 1 study of Advanced Solid Tumor that is active but no longer recruiting, run by Genmab. The registered enrollment target is 23 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (88% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06685068, a Phase 1 study of Advanced Solid Tumor, is active but no longer recruiting, sponsored by Genmab.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
23 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics (PK), anti-tumor activity and immunogenic potential of GEN1286 in participants with advanced solid tumors. This trial consists of 2 parts: * Part A: Dose escalation and dose level expansion * Part B: Tumor-specific expansion with dose optimization

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG GEN1286

Study Locations (4)

Massachusetts

  • Massachusetts General Hospital - Boston

Michigan

  • START Midwest - Grand Rapids

Texas

  • START San Antonio - San Antonio

Utah

  • START Mountain Region - West Valley City

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2024-11-13
Est. Completion 2028-06-29
Phase Phase 1
Genmab

45 total trials

What the registry record for NCT06685068 still lists

NCT06685068 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (88% lower).

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which GEN1286 is the first listed.

NCT06685068 reports a single indexed study location in Massachusetts, Michigan, Texas.

Frequently Asked Questions

What is clinical trial NCT06685068 about?

NCT06685068 is a clinical study titled "A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors". The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics (PK), anti-tumor activity and immunogenic potential of GEN1286 in participants with advanced solid tumors. This trial consists of 2 parts: * Part A: Dose escalation and dose level expansion * Part B: Tumor-specific...

What is the current status of trial NCT06685068?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2024-11-13. Estimated completion is 2028-06-29.

What conditions does trial NCT06685068 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT06685068?

The interventions under investigation include: GEN1286 (DRUG).

Who is sponsoring clinical trial NCT06685068?

This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06685068 being conducted?

This trial has 4 study locations across Massachusetts, Michigan, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06685068's enrollment target sits among peer trials

23 180th of 189 higher than 10 of 189 other Advanced Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03616041 · 23 participants

    Capsule Endoscopy for Severe Hematochezia

  • NCT04348747 · 23 participants · Phase 2

    Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

  • NCT04587687 · 23 participants · Phase 2

    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

  • NCT04715022 · 23 participants · Phase 1

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06685068, the US trial registry maintained by the National Library of Medicine. NCT06685068 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.